Infliximab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Infliximab and local guidelines before prescribing.
Mechanism
Chimeric monoclonal antibody neutralising TNF-alpha.
Uses
Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, sarcoidosis (selected).
Dosing
- IV hydrocortisone 100 mg four times daily (or IV methylprednisolone) in acute severe ulcerative colitis (Truelove and Witts criteria) - with VTE prophylaxis, stool cultures and C. difficile test; review on day 3 for rescue therapy (ciclosporin or infliximab) or surgery.
Gastroenterology: Anatomy Physiology Pharmacology - Rescue therapy: Infliximab (e.g. 5 mg/kg; some centres use higher or accelerated dosing) or ciclosporin .
Gastroenterology: Gastroenterology Emergencies (Complete) - Infliximab / ciclosporin Steroid-refractory UC | Rescue therapy (specialist); infliximab 5 mg/kg (higher or accelerated in some protocols).
Gastroenterology: Gastroenterology Emergencies (Complete) - Severe: Admit - IV hydrocortisone 100 mg four times daily or methylprednisolone 60 mg daily; rescue with infliximab or ciclosporin; colectomy if no response.
Gastroenterology: Inflammatory Bowel Disease
4 more dose entries from the chapters
- Infliximab (IV 5 mg/kg at weeks 0, 2 and 6, then every 8 weeks; subcutaneous versions are available) and adalimumab (subcutaneous).
Gastroenterology: Inflammatory Bowel Disease - Colitis | Diarrhoea, abdominal pain, blood. Exclude infection; steroids (prednisolone 1 mg/kg, or IV methylprednisolone if severe); infliximab or vedolizumab if no response in 48–72 hours
Oncology: Principles - Severe colitis - 7 or more stools a day above baseline, blood, pain, peritonism: admit, IV methylprednisolone 1–2 mg/kg, CT for perforation; infliximab if no response in 48–72 hours.
Oncology: Emergencies - Grade 2 - prednisolone 0.5–1 mg/kg; grade 3–4 - IV methylprednisolone; infliximab for refractory colitis, mycophenolate for hepatitis.
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology
Side effects
Infusion reactions, infections, headache; reactivated TB, demyelination, hepatotoxicity, lupus-like syndrome.
Interactions
Methotrexate or azathioprine reduce antibody formation; live vaccines contraindicated.
Contraindications and cautions
Sepsis, active TB, moderate to severe heart failure
Monitoring
TB screen, infection, drug levels
Pregnancy and breastfeeding
Limited data
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
TB, hepatitis B and varicella screening; drug and antibody levels in loss of response.
More from the textbook: uses, cautions and other points
- Refractory disease: Anti-TNF (infliximab) - especially for cardiac, neuro and skin disease.
Respiratory: Interstitial Lung Disease - Infliximab | Refractory sarcoidosis (cardiac, neuro, skin); screen for TB first.
Respiratory: Interstitial Lung Disease - Steroids (oral prednisolone or IV methylprednisolone) for moderate or severe events; further immunosuppression (e.g. infliximab for colitis) if refractory.
Respiratory: Lung Cancer - IV methylprednisolone; infliximab if no response.
Respiratory: Lung Cancer - Infliximab (IV), adalimumab (SC), golimumab (UC) | TNF-alpha | Moderate to severe Crohn's and UC, perianal fistulas; TB reactivation , serious infections, worsens heart failure, demyelination, drug-induced lupus, paradoxical psoriasis, lymphoma (especially with thiopurines); infusion reactions; antibody formation - check drug …
Gastroenterology: Anatomy Physiology Pharmacology - Biosimilars - cheaper versions of infliximab and adalimumab; switching is usually safe.
Gastroenterology: Anatomy Physiology Pharmacology
Where it is discussed in the book
- Respiratory: Interstitial Lung Disease (3 mentions)
- Respiratory: Lung Cancer (2 mentions)
- Gastroenterology: Anatomy Physiology Pharmacology (4 mentions)
- Gastroenterology: Gastroenterology Emergencies (Complete) (3 mentions)
- Gastroenterology: Inflammatory Bowel Disease (7 mentions)
- Neurology: Multiple Sclerosis and inflammatory disease (1 mention)
- Oncology: Principles (5 mentions)
- Oncology: Emergencies (2 mentions)
- Paediatrics: Infections in children (1 mention)
- Paediatrics: Gastroenterology and surgery in children (3 mentions)
- Dermatology: Skin basics, eczema and psoriasis (1 mention)
- Dermatology: Urticaria, drug reactions, blistering, ulcers and emergencies (2 mentions)
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Rheumatology: assessment, investigations and drugs (2 mentions)
- Rheumatology: Inflammatory arthritis (2 mentions)
- Rheumatology: Vasculitis, GCA and PMR (2 mentions)
- Rheumatology: Emergencies, pregnancy and other systemic diseases (1 mention)
- ID: Hospital infection, the immunocompromised host, vaccination and public health (3 mentions)
- Surgery: Colorectal and anal surgery (2 mentions)
- Clinical Immunology: Immune system basics and immunological investigations (2 mentions)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (4 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (12 mentions)
- Integrated respiratory chapter (5 mentions)
- Integrated paediatrics chapter (4 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)